Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
duloxetine + lidocaine is a fixed-combination drug product containing duloxetine, a serotonin and norepinephrine reuptake inhibitor (SNRI), and lidocaine, a local anesthetic. This combination is used for the management of conditions where both central sensitization (e.g., major depressive disorder, generalized anxiety disorder, neuropathic pain, fibromyalgia, chronic musculoskeletal pain) and local pain management (topical lidocaine for localized pain) are clinically warranted. Duloxetine acts centrally by inhibiting the reuptake of serotonin and norepinephrine, increasing their levels in the central nervous system and modulating pain signaling as well as mood. Lidocaine provides local anesthesia by blocking sodium channels in neuronal membranes, thus preventing the initiation and conduction of nerve impulses at the site of application. The two drugs are supplied together in a kit form for co-administration, targeting patients with complex pain that may benefit from both systemic and localized analgesic effects[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on duloxetine + lidocaine.